MR imaging of crohn disease: Use of perflubron as a gastrointestinal contrast agent

Clinton M. Anderson, Jeffrey J. Brown, Dennis M. Balfe, Jay Heiken, Joseph A. Borrello, Ray E. Clouse, Thomas K. Pilgram

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post‐perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity of bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.

Original languageEnglish (US)
Pages (from-to)491-496
Number of pages6
JournalJournal of Magnetic Resonance Imaging
Volume4
Issue number3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Gastrointestinal Agents
Crohn Disease
Contrast Media
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Glucagon
Abscess
Fistula
Tomography
perflubron
Population

Keywords

  • Comparative studies
  • Contrast enhancement
  • Intestines, diseases, 74.262
  • Intestines, MR, 74.12143
  • Perfluorooctylbromide

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Anderson, C. M., Brown, J. J., Balfe, D. M., Heiken, J., Borrello, J. A., Clouse, R. E., & Pilgram, T. K. (1994). MR imaging of crohn disease: Use of perflubron as a gastrointestinal contrast agent. Journal of Magnetic Resonance Imaging, 4(3), 491-496. https://doi.org/10.1002/jmri.1880040342

MR imaging of crohn disease : Use of perflubron as a gastrointestinal contrast agent. / Anderson, Clinton M.; Brown, Jeffrey J.; Balfe, Dennis M.; Heiken, Jay; Borrello, Joseph A.; Clouse, Ray E.; Pilgram, Thomas K.

In: Journal of Magnetic Resonance Imaging, Vol. 4, No. 3, 01.01.1994, p. 491-496.

Research output: Contribution to journalArticle

Anderson, CM, Brown, JJ, Balfe, DM, Heiken, J, Borrello, JA, Clouse, RE & Pilgram, TK 1994, 'MR imaging of crohn disease: Use of perflubron as a gastrointestinal contrast agent', Journal of Magnetic Resonance Imaging, vol. 4, no. 3, pp. 491-496. https://doi.org/10.1002/jmri.1880040342
Anderson, Clinton M. ; Brown, Jeffrey J. ; Balfe, Dennis M. ; Heiken, Jay ; Borrello, Joseph A. ; Clouse, Ray E. ; Pilgram, Thomas K. / MR imaging of crohn disease : Use of perflubron as a gastrointestinal contrast agent. In: Journal of Magnetic Resonance Imaging. 1994 ; Vol. 4, No. 3. pp. 491-496.
@article{c747587681074023af476d9c19461a57,
title = "MR imaging of crohn disease: Use of perflubron as a gastrointestinal contrast agent",
abstract = "This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post‐perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity of bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.",
keywords = "Comparative studies, Contrast enhancement, Intestines, diseases, 74.262, Intestines, MR, 74.12143, Perfluorooctylbromide",
author = "Anderson, {Clinton M.} and Brown, {Jeffrey J.} and Balfe, {Dennis M.} and Jay Heiken and Borrello, {Joseph A.} and Clouse, {Ray E.} and Pilgram, {Thomas K.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/jmri.1880040342",
language = "English (US)",
volume = "4",
pages = "491--496",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - MR imaging of crohn disease

T2 - Use of perflubron as a gastrointestinal contrast agent

AU - Anderson, Clinton M.

AU - Brown, Jeffrey J.

AU - Balfe, Dennis M.

AU - Heiken, Jay

AU - Borrello, Joseph A.

AU - Clouse, Ray E.

AU - Pilgram, Thomas K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post‐perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity of bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.

AB - This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post‐perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity of bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.

KW - Comparative studies

KW - Contrast enhancement

KW - Intestines, diseases, 74.262

KW - Intestines, MR, 74.12143

KW - Perfluorooctylbromide

UR - http://www.scopus.com/inward/record.url?scp=0028434416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028434416&partnerID=8YFLogxK

U2 - 10.1002/jmri.1880040342

DO - 10.1002/jmri.1880040342

M3 - Article

C2 - 8061454

AN - SCOPUS:0028434416

VL - 4

SP - 491

EP - 496

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 3

ER -